These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 12427969)

  • 21. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
    Schessl C; Rawat VP; Cusan M; Deshpande A; Kohl TM; Rosten PM; Spiekermann K; Humphries RK; Schnittger S; Kern W; Hiddemann W; Quintanilla-Martinez L; Bohlander SK; Feuring-Buske M; Buske C
    J Clin Invest; 2005 Aug; 115(8):2159-68. PubMed ID: 16025155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.
    Lutterbach B; Westendorf JJ; Linggi B; Patten A; Moniwa M; Davie JR; Huynh KD; Bardwell VJ; Lavinsky RM; Rosenfeld MG; Glass C; Seto E; Hiebert SW
    Mol Cell Biol; 1998 Dec; 18(12):7176-84. PubMed ID: 9819404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
    Wichmann C; Grez M; Lausen J
    Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular basis of the t(8;21) translocation in acute myeloid leukaemia.
    Ohki M
    Semin Cancer Biol; 1993 Dec; 4(6):369-75. PubMed ID: 8142622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
    Licht JD
    Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
    [No Abstract]   [Full Text] [Related]  

  • 27. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ETO (MTG8) gene family.
    Davis JN; McGhee L; Meyers S
    Gene; 2003 Jan; 303():1-10. PubMed ID: 12559562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
    Lenny N; Meyers S; Hiebert SW
    Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
    Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
    Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8).
    Odaka Y; Mally A; Elliott LT; Meyers S
    Oncogene; 2000 Jul; 19(32):3584-97. PubMed ID: 10951564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
    Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
    Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
    Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
    Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
    Lutterbach B; Sun D; Schuetz J; Hiebert SW
    Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor.
    Wildonger J; Mann RS
    Development; 2005 May; 132(10):2263-72. PubMed ID: 15829516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leukemia-associated AML1/ETO (8;21) chromosomal translocation protein increases the cellular representation of PML bodies.
    McNeil S; Javed A; Harrington KS; Lian JB; Stein JL; van Wijnen AJ; Stein GS
    J Cell Biochem; 2000 Jul; 79(1):103-12. PubMed ID: 10906759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
    Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
    Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.